Astellas Pharma (ALPMY) and Pfizer (PFE) announced longer-term follow-up results from an open-label extension of the Phase 3 ...

CompanyOverview\|NYSE:PFE] A dividend yield that surpasses 7.5% from a pharmaceutical sector giant like Pfizer Inc. (NYSE: PFE) certainly catches the eye of income- ...

Pfizer is paying $1.25 billion to join the PD-(L1)xVEGF bispecific race. | Pfizer is paying $1.25 billion to join the ...

Pfizer Inc. has secured an exclusive global licensing agreement with 3SBio, Inc., a leading Chinese biopharma, for SSGJ-707.

A grantee of the Gates Foundation, Hong Kong-based Phase Scientific built a business on the back of Covid-19 tests. Up next: ...

Here's a recap of the week’s most important stories.

An eight-member panel voted unanimously against wider use of Pfizer’s Talzenna in advanced prostate cancer. Elsewhere, U.K. regulators cleared Sarepta to restart an Elevidys study and Altos Labs ...

While gaps persist in workforce retention, infrastructure, and equitable access, the transformation of Nigeria’s health ...

Pfizer has struck a high-stakes deal with 3SBio to license SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, outside of China. Unlike current drugs that hit only PD-1, this antibody aims at two ...

The global monoclonal antibodies market is poised for robust expansion, projected to surge from USD 208.32 billion in 2022 to USD 647.01 billion by 2032, reflecting a CAGR of 12% over the forecast ...

Talzenna is currently approved in combination with Xtandi (enzalutamide) for individuals with castration-resistant prostate ...

In exchange, 3SBio will receive $1.25bn upfront from Pfizer and will be eligible for certain development, regulatory and ...